Tags

Type your tag names separated by a space and hit enter

Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome.
Anticancer Res. 1999 Mar-Apr; 19(2B):1401-5.AR

Abstract

Substantial experimental and clinical evidence links tumor growth, progression and metastatic potential with neoangiogenesis. This process is modulated by several angiogenic growth factors, such as vascular endothelial growth factor (VEGF). Little data are currently available on serum VEGF levels in cancer patients. In the present retrospective investigation preoperative serum VEGF was higher in 53 patients with epithelial ovarian cancer than in 25 patients with benign ovarian disease as controls (median, range: 229.7, 23.5-1807.5 pg/ml versus 140.3, 14.7-1038.7 pg/ml, p = 0.034). With regard to FIGO stage, antigen values were significantly elevated in stage III-IV (p = 0.027) but not in stage I-II ovarian cancer patients when compared to controls. In patients with advanced disease preoperative serum VEGE was significantly related to the presence of ascites (p = 0.013), but not to common prognostic variables, response to chemotherapy and survival. In conclusion, preoperative serum VEGF assay reflects tumor progression and ascites generation in epithelial ovarian cancer, but it seems to have a limited predictive and prognostic value in patients with advanced disease.

Authors+Show Affiliations

Department of Procreative Medicine, University of Pisa, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

10365113

Citation

Gadducci, A, et al. "Serum Preoperative Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Cancer: Relationship With Prognostic Variables and Clinical Outcome." Anticancer Research, vol. 19, no. 2B, 1999, pp. 1401-5.
Gadducci A, Ferdeghini M, Fanucchi A, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19(2B):1401-5.
Gadducci, A., Ferdeghini, M., Fanucchi, A., Annicchiarico, C., Ciampi, B., Prontera, C., & Genazzani, A. R. (1999). Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Research, 19(2B), 1401-5.
Gadducci A, et al. Serum Preoperative Vascular Endothelial Growth Factor (VEGF) in Epithelial Ovarian Cancer: Relationship With Prognostic Variables and Clinical Outcome. Anticancer Res. 1999 Mar-Apr;19(2B):1401-5. PubMed PMID: 10365113.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. AU - Gadducci,A, AU - Ferdeghini,M, AU - Fanucchi,A, AU - Annicchiarico,C, AU - Ciampi,B, AU - Prontera,C, AU - Genazzani,A R, PY - 1999/6/12/pubmed PY - 1999/6/12/medline PY - 1999/6/12/entrez SP - 1401 EP - 5 JF - Anticancer research JO - Anticancer Res VL - 19 IS - 2B N2 - Substantial experimental and clinical evidence links tumor growth, progression and metastatic potential with neoangiogenesis. This process is modulated by several angiogenic growth factors, such as vascular endothelial growth factor (VEGF). Little data are currently available on serum VEGF levels in cancer patients. In the present retrospective investigation preoperative serum VEGF was higher in 53 patients with epithelial ovarian cancer than in 25 patients with benign ovarian disease as controls (median, range: 229.7, 23.5-1807.5 pg/ml versus 140.3, 14.7-1038.7 pg/ml, p = 0.034). With regard to FIGO stage, antigen values were significantly elevated in stage III-IV (p = 0.027) but not in stage I-II ovarian cancer patients when compared to controls. In patients with advanced disease preoperative serum VEGE was significantly related to the presence of ascites (p = 0.013), but not to common prognostic variables, response to chemotherapy and survival. In conclusion, preoperative serum VEGF assay reflects tumor progression and ascites generation in epithelial ovarian cancer, but it seems to have a limited predictive and prognostic value in patients with advanced disease. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/10365113/Serum_preoperative_vascular_endothelial_growth_factor__VEGF__in_epithelial_ovarian_cancer:_relationship_with_prognostic_variables_and_clinical_outcome_ L2 - http://www.diseaseinfosearch.org/result/5509 DB - PRIME DP - Unbound Medicine ER -